Why does Hexarelin cause desensitisation?

With repeated use, the GH-releasing effect of Hexarelin diminishes, likely due to downregulation of ghrelin receptors. This limits its utility for long-term GH elevation.

Is Hexarelin good for the heart?

Research has shown cardioprotective effects in laboratory and animal studies. However, Hexarelin is not approved for any cardiac indication, and human clinical data for cardiac applications is limited.

How does Hexarelin compare to other GHRPs?

Hexarelin is one of the most potent for acute GH release but has more pronounced desensitisation with repeated use. Ipamorelin is more selective with fewer side effects; GHRP-6 causes more hunger.

Fact-checked by the Peptide Authority Editorial Board · Last reviewed: 1 February 2026

Share:X Post LinkedIn

Hormonal & Endocrine•Updated 2026-02-01•5 min read

What Is Hexarelin? Benefits, Research & Safety

A potent growth hormone-releasing peptide with notable cardioprotective properties independent of GH release.

Share:X Post LinkedIn

Also known as:

Examorelin

HEX

DAnimal/cell evidence onlyUK: Unlicensed (UK)WADA: Prohibited in sport

UK summary: Not a licensed UK medicine. Potent GHRP with research interest in cardioprotection. Prohibited at all times under WADA S2. Sometimes cited for tachyphylaxis (reduced effect with chronic use) more than other GHRPs.

Quick Facts

Overview

Hexarelin is a synthetic hexapeptide growth hormone-releasing peptide (GHRP) that stimulates GH secretion through the ghrelin receptor. It is considered one of the most potent GHRPs in terms of GH release, producing robust elevations in growth hormone even with single doses. Beyond its GH-releasing properties, Hexarelin has demonstrated significant cardioprotective effects in research. Studies suggest it can protect heart tissue from ischemia, promote healing after cardiac injury, and exert beneficial effects on cardiac function that may be partly independent of its GH-releasing action. Hexarelin was studied in clinical trials for various indications including GH deficiency and cardiac conditions. While it showed efficacy, it was not ultimately approved for therapeutic use. Unlike some other GHRPs, Hexarelin has been associated with the development of desensitisation with repeated use, potentially limiting its long-term effectiveness. The peptide remains a research compound not approved for human therapeutic use.

Evidence standards summary

Hexarelin — evidence and risk at a glance

Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.

01Evidence snapshot

DAnimal/cell evidence onlyOverall grade against our evidence grading methodology.

Not a licensed UK medicine. Potent GHRP with research interest in cardioprotection. Prohibited at all times under WADA S2. Sometimes cited for tachyphylaxis (reduced effect with chronic use) more than other GHRPs.

02Human evidence grade

DAnimal/cell evidence onlyStrength of evidence from published human trials.

03Preclinical evidence grade

BModerate human evidenceAnimal-model and in-vitro evidence quality.

04Regulatory status

UK: Not licensed for human use. Research compound only.
EU: Not approved for therapeutic use.
Notes: Hexarelin is not approved by any regulatory authority. It is prohibited in sports by WADA. Available only as a research compound.

05Approved medical uses

None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)

06Unapproved / promotional claims

Most potent GHRP for biggest GH spike.
Cardioprotective for athletes during heavy training.
Safe long-term for body composition.
Cleaner cortisol profile than GHRP-6.

07Common internet claims

Marketed in bodybuilding and 'anti-ageing' stacks.
Sold online as the most potent GHRP.
Promoted for cardioprotection extrapolated from animal data.

08Claim vs evidence

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“Cardioprotective for athletes / strength trainers”	D	No	High	Animal-model and ex-vivo cardiac data exist; human cardioprotection claims are not established.
“Most potent GHRP — biggest GH spike”	C	Limited	High	Short-term studies show high GH-release potency; potency is not the same as clinical benefit.
“Use long-term for body composition”	E	No	High	Long-term safety in healthy adults is not established; chronic GHRP use raises tachyphylaxis and cortisol concerns.

09Safety uncertainty score

High

Limited human safety data; meaningful uncertainty about rare or long-term effects.

10Known adverse signals

Tachyphylaxis (diminishing effect) with chronic use.
Cortisol and prolactin elevation.
Water retention, joint pain, carpal tunnel symptoms.
Theoretical oncologic risk from sustained IGF-1 elevation.

11Drug-interaction uncertainty

High

Interaction picture sparse; meaningful uncertainty when combined with other medicines.

12Anti-doping status

WADA: Prohibited in sportWADA strict-liability framing applies.

13UK legal position

UK: Unlicensed (UK)

Not licensed for human use. Research compound only.

Read the full UK legal guide → Peptides and athletes (UK)

14EU legal position

Not approved for therapeutic use.

15What this page cannot tell you

Whether a UK-purchased vial contains Hexarelin at the labelled concentration.
Whether cardioprotective effects in animal studies translate to humans.
What chronic use does to natural ghrelin signalling and hunger regulation.
WADA detection windows — assume positive on test, strict-liability.

16Last reviewed

Last reviewed: 1 February 2026

Next review due: 1 February 2027

Spotted an error or something out of date? Send a correction.

17Citation quality score

CLimited human evidenceQuality of the sources we cite, graded against the evidence grading methodology.

18Research gaps

Cardiac outcome trials in humans absent.
Phase 3 trials for any indication absent.
Long-term safety unstudied.
Combination-stack safety with CJC-1295, MK-677 uncharacterised.

19Safer alternatives / established care pathways

Endocrinologist review for adult GH-deficiency with formal testing.
Cardiac risk assessment and standard NHS cardioprotective interventions (statins, BP control, exercise).
Licensed recombinant HGH under specialist supervision where confirmed deficiency.

20Doctor discussion prompts

Questions to ask a qualified clinician

These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

Is Hexarelin a licensed UK medicine?
What is the WADA position?
What licensed alternatives exist for the underlying issue I'm asking about?

Discovery & History

Hexarelin was developed as part of ongoing research into growth hormone secretagogues following the initial discovery of GHRPs in the 1980s. It was designed to be a potent and stable GH-releasing peptide based on structure-activity relationship studies. Preclinical research revealed that Hexarelin was among the most potent GHRPs, producing significant GH release. Clinical trials were conducted for potential use in GH deficiency and other conditions. Research also identified Hexarelin's cardioprotective properties, which generated interest in potential cardiovascular applications. Studies showed beneficial effects on ischemia-reperfusion injury and cardiac function. However, clinical development did not result in regulatory approval. One limitation identified was the development of desensitisation with repeated administration—the GH-releasing effect appeared to diminish over time, potentially limiting long-term therapeutic utility. Hexarelin remains an important research tool and continues to be studied, particularly for its cardiac effects.

Mechanism of Action

Hexarelin works through the ghrelin receptor with additional cardiac mechanisms: **GHS-R Activation** Hexarelin potently activates the growth hormone secretagogue receptor (GHS-R) on pituitary somatotrophs, producing robust GH release. **Cardiac Effects Independent of GH** Some of Hexarelin's cardioprotective effects appear to be independent of GH release. The peptide may directly affect cardiac cells through specific receptors or signalling pathways not yet fully characterised. **Effects on Multiple Hormones** Like other GHRPs, Hexarelin affects cortisol, prolactin, and ACTH to varying degrees. It may have more pronounced effects on these hormones compared to more selective alternatives. **Desensitisation** With repeated use, Hexarelin's GH-releasing effect tends to diminish—a phenomenon called desensitisation or tachyphylaxis. This may involve downregulation of GHS receptors. **Potential for Cardiac Receptor Activation** Research suggests Hexarelin may activate specific cardiac receptors (possibly CD36 or related receptors) that mediate cardioprotective effects independent of the ghrelin receptor.

Researched Benefits

Based on preclinical and clinical research findings:

1
Potent growth hormone release (among the strongest GHRPs)
2
Cardioprotective effects in research models
3
Protection against ischemia-reperfusion injury
4
Elevated IGF-1 levels
5
Potential benefits for cardiac function

Claim vs Evidence

How popular claims about Hexarelin stack up against the current research, graded using our public evidence grading methodology.

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“Cardioprotective for athletes / strength trainers”	D	No	High	Animal-model and ex-vivo cardiac data exist; human cardioprotection claims are not established.
“Most potent GHRP — biggest GH spike”	C	Limited	High	Short-term studies show high GH-release potency; potency is not the same as clinical benefit.
“Use long-term for body composition”	E	No	High	Long-term safety in healthy adults is not established; chronic GHRP use raises tachyphylaxis and cortisol concerns.

Theoretical Dosing & Protocols

⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.

Theoretical Dosage	100-200 mcg per dose
Frequency	2-3 times daily (note: desensitisation may occur)
Duration	Often used in shorter cycles due to desensitisation
Notes	Hexarelin is not approved for therapeutic use. Desensitisation with repeated use may limit long-term effectiveness. Cycling or intermittent use may be considered. Any use should be under medical supervision.

Administration Routes

Routes studied in research settings (educational only):

Subcutaneous injection
Intravenous (research settings)

Half-Life	Stability
Approximately 70 minutes (longer than some other GHRPs)	Lyophilised powder stable when properly stored

Safety Profile & Known Risks

Commonly Reported Side Effects

Flushing
Water retention
Tingling or numbness
Injection site reactions
Cortisol elevation

Rare Risks & Concerns

Desensitisation with chronic use
Unknown long-term effects
Effects on other hormonal axes
Theoretical concerns with tumour growth

Contraindications

Active malignancy
Pregnancy and breastfeeding
Unstable cardiac conditions
Diabetes (monitor closely)

UK & EU Regulatory Context

🇬🇧 United Kingdom

Not licensed for human use. Research compound only.

🇪🇺 European Union

Not approved for therapeutic use.

Hexarelin is not approved by any regulatory authority. It is prohibited in sports by WADA. Available only as a research compound.

Clinical Studies Summary

Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.

Ghrelin shows no interaction with HEX, whereas it has a synergistical effect with GHRH on GH secretion. Thus, ghrelin is a new hormone playing a major role in the control of somatotroph secretion in humans, and its effects are imitated by nonnatural GHS.

J Clin Endocrinol Metab. 2001View on PubMed

Desmopressin and hexarelin tests in alcohol-induced pseudo-Cushing's syndrome.

These data suggest that either the hexarelin or desmopressin test can be used to differentiate patients with Cushing's disease from subjects with alcohol-dependent pseudo-Cushing's syndrome.

J Intern Med. 2000View on PubMed

Tyr-Ala-Hexarelin, a synthetic octapeptide, possesses the same endocrine activities of Hexarelin and GHRP-2 in humans.

In conclusion, the present results demonstrate that in humans Tyr-Ala-HEX is a GH secretagogue as potent as HEX and GHRP-2, two GHRP-6 superanalogs. Tyr-Ala-HEX also shares with HEX and GHRP-2 the same PRL- ACTH- and cortisol-releasing activity.

J Endocrinol Invest. 1999View on PubMed

Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans.

These findings suggest that in man, the acute administration of Hexarelin exerts a short-lasting, positive inotropic effect. This effect seems GH-independent and might be mediated by specific GHS myocardial receptors.

J Endocrinol Invest. 1999View on PubMed

The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin.

Our data suggest that the effect of GHSs on the HPA axis involve at least in part the stimulation of AVP release. In summary, we have shown that in healthy male volunteers, the effect of hexarelin on the HPA axis does not involve CRH, but may occur through the stimulation of AVP release.

J Clin Endocrinol Metab. 1999View on PubMed

Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.

Our results demonstrate that pyridostigmine is able to enhance the GH response only to a very low dose Hexarelin which, in turn, potentiates the GHRH-induced GH rise to the same extent as pyridostigmine. As there is evidence that GHRPs do not inhibit hypothalamic somatostatin release, these findings are consistent with the hypothesis that they act by antagonizing somatostatin activity and/or through unknown factors.

Clin Endocrinol (Oxf). 1997View on PubMed

Registered Trials & Regulatory Status

Registered trials

Currently recruiting

Furthest phase

none

Approved product

1 of 3 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.

NobelZygoma TiUltra Implant System Study

Status: Not Yet Recruiting · 85 participants · Nobel Biocare

Conditions: Edentulous Maxilla, Maxillary Bone Loss, Atrophic Maxilla

No results postedNCT07258940

A PAC Post-Market Clinical Study to Demonstrate Color Change in the WoundCue™ Kit When an Elevated Inhibitory Bacterial and/or Fungal Load is Present in a Wound

Status: Not Yet Recruiting · 50 participants · ParaNano, Inc.

Conditions: Wound Care

No results postedNCT07349485

Effect of Heated Water-Based Versus Land-Based Exercise Training on Hemodynamic Variables, Functional Capacity and Quality of Life in Older Hypertensive

Status: Recruiting · 60 participants · Universidade Estadual Paulista Júlio de Mesquita Filho

Conditions: Hypertension, Aging, Exercise

No results postedNCT07131748

Home Exercise Program for Homebound Older Adults

Status: Completed · 19 participants · University of Maryland, Baltimore

Conditions: Aging

No results postedNCT04034888

Short Dental Implants (5 mm) Versus Long Dental Implants (10 mm)

Status: Completed · 34 participants · University of Michigan

Conditions: Bone Loss, Alveolar

Results postedNCT04144322

An Implant With an Acid-etched Fixture Surface and Internal-hex Collar May Achieve Greater Osseointegration.

Status: Completed · 58 participants · Université de Montréal

Conditions: Jaw, Edentulous, Dental Implant

Results postedNCT01641198

Adverse event reports (FDA FAERS)

Not applicable: no licensed product contains this peptide, so it is not reported through FAERS. This is an absence of surveillance, not evidence of safety.

Source: ClinicalTrials.gov and openFDA. Updated automatically.

Looking for Hexarelin?

Source research-grade Hexarelin from a trusted UK supplier — third-party tested with certificate of analysis.

View at Supplier

Frequently Asked Questions

Questions to ask a qualified clinician about Hexarelin